T-DM1

This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.

Immunotherapy and future directions in oncology

Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule

Latest news

EU backs Roche’s Kadcyla in breast cancer

Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its
Roche's Herceptin follow-up cleared in US

Roche's Herceptin follow-up cleared in US. FDA approval for Kadcyla (formerly T-DM1) in breast cancer. ... The FDA has given the go-ahead to Kadcyla, formerly known as T-DM1, as a therapy for patients with HER2-positive, late-stage metastatic breast
Product updates from Japan

pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation
Roche delivers solid sales gain in 2012

Perjeta has been tipped as a future blockbuster, as has Herceptin follow-up trastuzumab emtansine ( T-DM1), which is filed in the US and Europe and expected to be on the
Celgene signs $500m antibody deal with Sutro

In addition, Roche is involved in the advancement of antibody-drug conjugates with T-DM1, which has caused great excitement for its potential in the treatment of breast cancer.

More from news
Approximately 4 fully matching, plus 17 partially matching documents found.

Latest Intelligence

An eye towards the biobetter in South Korea

It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Roche names John Reed as new head of early research

investigational medicines, such as breast cancer drug T-DM1.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Consumer Health Account Director: Circa £60, 000 Gym and More

Senior Account Manager: Negotiable

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Senior Account Executive, London, Medical Communications: Excellent package

Associate Editorial Director – Med Comms – London: Salary TBC

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Senior Systematic Review Analyst - Oxford: Negotiable

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Project / Account Manager (Medical Education): Salary TBC

Associate Director, Market Access & HEOR – North-West: Negotiable

Medical/ Scientific Director: Salary TBC

Senior Medical Writer: Great salary and benefits

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Subscribe to our email news alerts

PMHub

Add my company

Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...